EyePoint Pharmaceuticals
Update in progressEYPT (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
EyePoint, Inc. develops and commercializes therapies for serious retinal diseases, using its Durasert E bioerodible technology for sustained intraocular drug delivery. Its lead candidate, DURAVYU, combines vorolanib with Durasert E and targets VEGF-mediated diseases; it is in Phase 3 for wet AMD and DME. The pipeline also includes EYP-2301, a TIE-2 agonist in preclinical development. Formerly EyePoint Pharmaceuticals, it changed its name in December 2025. Based in Watertown, MA, founded 2000.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Jay S. Duker M.D.
- Founded2000
- Employees214
- Websiteeyepoint.bio
Identifiers
- ISINUS30233G2093
- FIGIBBG000F90JX5
- LEI549300QE1RU34T50MR69
- CUSIP30233G100
- CIK0001314102